Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
Last Updated: Friday, July 17, 2026
This review article focuses on the clinical landscape of HER2-positive breast cancer and, in particular, the use of antibody-drug conjugates and how to treat patients after their disease progresses on trastuzumab deruxtecan, including novel therapeutic agents and combinatorial regimens.